1330782-76-7 (TAK-931,Simurosertib)

2-(2S)-1-氮杂双环[2.2.2]辛-2-基-6-(3-甲基-1H-吡唑-4-基)-噻吩并[3,2-d]嘧啶-4(3H)-酮;

Simurosertib;Tak 931;LST350G3XU;Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-;TAK931;2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one;2-((2S)-1-azabicyclo(2.2.2)octan-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno(3,2-d)pyrimidin-4-one;2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one;TAK-931;TAK931F;MS-25218;(S)-6-(3-methyl-1H-pyrazol-4-yl)-2-(quinuclidin-2-yl)thieno[3,2-d]pyrimidin-4(3H)-one;Cell Division Cycle 7 Inhibitor TAK-931;WHO 11008;Simurosertib [USAN];2-((2S)-1-Azabicyclo[2.2.2]oct-2-yl)-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one;example 108 (US9655900B2);SIMUROSERTIB [INN];2-((2S)-1-AZABICYCLO(2.2.2)OCT-2-YL)-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO(3,2-D)PYRIMIDIN-4(3H)-ONE;GTPL10317;1330782-76-7;2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one;2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one;Simurosertib (USAN/INN);SCHEMBL19410618;SCHEMBL12459022;AKOS040736357;simurosertibum;SIMUROSERTIB [WHO-DD];BDBM50506350;UNII-LST350G3XU;ZB1533;2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one;O1V;SCHEMBL21451200;F90328;example 108 [US9655900B2];XGVXKJKTISMIOW-ZDUSSCGKSA-N;GLXC-20157;HY-100888;Simurosertib (TAK-931)?;CS-0020550;CHEMBL4297644;EX-A2702;AC-36305;D12176;

XGVXKJKTISMIOW-ZDUSSCGKSA-N

1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1

S1C(C2C=NNC=2C)=CC2=C1C(NC([C@@H]1CC3CCN1CC3)=N2)=O